Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
3.600
-0.120 (-3.23%)
At close: Jun 13, 2025, 4:00 PM
3.630
+0.030 (0.83%)
After-hours: Jun 13, 2025, 7:57 PM EDT
Ardelyx Revenue
Ardelyx had revenue of $74.11M in the quarter ending March 31, 2025, with 61.04% growth. This brings the company's revenue in the last twelve months to $361.71M, up 127.33% year-over-year. In the year 2024, Ardelyx had annual revenue of $333.62M with 168.06% growth.
Revenue (ttm)
$361.71M
Revenue Growth
+127.33%
P/S Ratio
2.36
Revenue / Employee
$915,711
Employees
395
Market Cap
861.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ARDX News
- 12 days ago - Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer - GlobeNewsWire
- 24 days ago - Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 - GlobeNewsWire
- 5 weeks ago - Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference - GlobeNewsWire
- 6 weeks ago - Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty - Seeking Alpha
- 6 weeks ago - Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - GlobeNewsWire
- 7 weeks ago - Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference - GlobeNewsWire